380 Preliminary results of an ongoing phase I trial of FT500, a first-in-class, off-the-shelf, induced pluripotent stem cell (iPSC) derived natural killer (NK) cell therapy in adva...

by Sarah Cooley, Sandip Patel, Kimberly Musni, Marlisa Anderson, Wayne Chu
Published 2020-11-01